We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies

News   Aug 12, 2015

 
Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies
 
 
Advertisement
 

RELATED ARTICLES

Discovering the Strategies Tumor Cells Use To Evade Immune Attack

News

A new study has uncovered the strategies tumor cells use to evade immune system attack. The method developed for this work contributes to a better understanding of the "arms race" between immune defense and disease.

READ MORE

Team Develops Synthetic Blood-Thinner With No Bleeding Side Effects

News

Scientists have developed a highly selective and highly stable synthetic blood-thinning molecule that, unlike others, doesn’t cause bleeding adverse effects.

READ MORE

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE